Heart; Surgery, Heart, Functional Disturbance as Result
Conditions
Keywords
Del Nido Cardioplegia, Cardioplegia, Adult Cardiac Surgery, Myocardial protection, Heart surgery
Brief summary
Cardioplegia solutions have been used for myocardial protection in cardiac surgery for decades. Different cardioplegic strategies have been evaluated. Del Nido cardioplegia was initially used in pediatric patients and has been expanding into adult cardiac centers over the last decade. It can be used as a single dose and it is a reasonable tool do decrease cardioplegic interventions. Recent meta-analysis based on 9 retrospective studies has shown that clinical outcomes of Del Nido cardioplegia are noninferior to the outcomes of conventional cardioplegia in adult cardiac surgery. To assess the potencial benefits of Del Nido cardioplegia we performed this clinical trial to evaluate superiority of Del Nido cardioplegia compared to cold blood cardioplegia in terms of myocardial protection and clinical-related outcomes. 474 participants will be randomized either into Del Nido cardioplegia protocol or into the cold blood cardioplegia protocol. Perioperative outcomes will be presented.
Detailed description
This clinical trial is performed at Puerta de Hierro Hospital in Spain. The protocol has been approved by institutional ethical committee and Spanish Agency of medicines and medical devices (AEMPS). The aim of the study is to evaluate superiority of Del Nido cardioplegia solution compared to cold blood cardioplegia solution in terms of myocardial protection and clinical-related outcomes. According to results in recent meta-analysis, the author estimated a total sample size of 474 participants to give 80 % of power at the 5% significant level. Participants aged 18 years or older undergoing elective cardiac surgery are randomized 1:1 to receive Del Nido cardioplegia solution (study group) and cold blood cardioplegia solution (control group). Primary outcome will be assessed by biochemical variables of myocardial injury (troponin T level at inmediate post-op, 3-12 hours, 12-24 hours, 24-48 hours post-op); and clinical variables: Presence of acute myocardial infarction within 72 hours after surgery, Prolonged low cardiac output, Prolonged postoperative vasoplegia within 48 hours after surgery and/or Ventricular tachyarrythmias within 24 hours after surgery. Secondary outcomes include intraoperative variables of myocardial protection (incidence of ventricular fibrillation, inotropic and vasopressor support at the end of surgical intervention, cardiopulmonary bypass time, aortic cross-clamp time) and postoperative clinical outcomes variables (mechanical ventilation time, incidence of delirium, stroke, acute renal failure, atrial fibrillation, length of stay in intensive care unit, length of stay in hospital and In-hospital mortality).
Interventions
Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml). Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq.
DRUGCOLD BLOOD BASED CARDIOPLEGIA
Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
Sponsors
JESSICA GARCIA SUAREZ
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients age 18 years or older undergoing adult cardiac surgery. * Elective surgical procedures requiring cardiopulmonary bypass and myocardial arrest.
Exclusion criteria
* Emergency surgery. * Patients on preoperative inotropic support and/or mechanical circulatory support. * Patient who refuse to participate in the study. * Lidocaine allergy. * Port access mitral valve surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood troponin levels. | Up to 48 hours | Biochemical variables of myocardial injury: Blood troponin levels measured at admission in intensive care unit, 12, 24, 48 hours post-op. |
| Acute cardiovascular event. | Up to 72 hours | Composite outcome of clinical events Prolonged low cardiac output, Prolonged postoperative vasoplegia, Ventricular tachyarrythmias and/or Acute myocardial infarction. * Prolonged low cardiac output. Inotropic pharmacologic support more than 48 hours in intensive care unit and/or mechanical circulatory support. * Prolonged postoperative vasoplegia. Vasopressor support more than 48 hours in intensive care unit. * Ventricular tachyarrythmias. Ventricular fibrillation and hemodynamically unstable ventricular tachycardia within 24 hours after surgery. * Acute myocardial infarction within 72 hours after surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardioplegia delivery. | Intraoperative. | Cardioplegia delivery (antegrade, retrograde, both). |
| Cardiopulmonary bypass time (CBP). | Intraoperative. | Duration of cardiopulmonary bypass (CBP) (min). |
| Aortic cross-clamp time | Intraoperative. | Duration of aortic cross-clamp time (min). |
| Return to cardiopulmonary bypass. | Intraoperative | Failure to separate from cardiopulmonary bypass (Y/N). |
| Intraoperative packed red blood cells transfusion. | Intraoperative | Intraoperative packed red blood cells transfusion (U). |
| Intraoperative maximal blood glucose concentration. | Intraoperative | Intraoperative maximal blood glucose concentration (mg/dl). |
| Postoperative atrial fibrillation. | Up to 2 weeks. | New-onset atrial fibrillation or hemodynamically unstable atrial fibrillation that requires treatment (Y/N). |
| Reoperation. | Up to 24 hours. | Reoperation within 24 hours after surgery (Y/N). |
| Inotropic or vasopressor support in intensive care unit. | At admission in intensive care unit, 24, 48 hours. | Inotropic or vasopressor support in intensive care unit (Y/N). |
| Ventricular fibrillation after aortic cross-clamp removal. | Intraoperative. | Incidence of ventricular fibrillation after aortic cross-clamp removal (Y/N). |
| Time to extubation. | Up to 2 weeks. | Mechanical ventilation time (min). |
| Acute renal failure. | Up to 2 weeks. | Incidence of renal failure (Requirement for postoperative renal replacement therapy) (Y/N). |
| Ischemic stroke. | Up to 2 weeks. | Incidence of ischemic stroke (Y/N). |
| Delirium. | Up to 2 weeks. | Incidence of delirium (Y/N). |
| Postoperative packed red blood cells transfusion. | Up to 1 week. | Postoperative packed red blood cells transfusion (U) |
| Length of stay in intensive care unit | through study completion, an average 1 month. | Length of stay in intensive care unit (days). |
| Length of stay in hospital | through study completion, an average 6 months. | Length of stay in hospital (days). |
| Postoperative ventricular ejection fraction change. | through study completion, an average 6 months. | Postoperative ventricular ejection fraction (LVEF) change (Y/N). |
| Mortality. | through study completion, an average 6 months. | Mortality (Y/N). |
| Duration of inotropic support after cardiopulmonary bypass. | Up to 2 weeks. | Duration of inotropic support after cardiopulmonary bypass (hours). |
| Defibrillation requirement. | Intraoperative. | Defibrillation requirement after aortic cross-clamp removal (Y/N). |
Countries
Spain
Outcome results
None listed